A Clinical Trial Study to Evaluate the Pharmacokinetic Interaction and Safety Between BR1019-1 and BR1019-2 in Healthy Adult Subjects
Study Details
Study Description
Brief Summary
The purpose of this study is to evaluate the pharmacokinetic interaction and safety between BR1019-1 and BR1019-2 in healthy adult subjects.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 1 |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Sequence 1 The Investigational products will be administered according to the treatment groups(A,B,C) assigned to each sequence group in Period 1, Period 2, and Period 3. *sequence 1: A-B-C |
Drug: BR1019-1
Treatment group A : One tablet of BR1019-1 administered alone once daily for 7 days.
Drug: BR1019-2
Treatment group B : One tablet of BR1019-2 administered alone once daily for 7 days.
Drug: BR1019-1 + BR1019-2
Treatment group C : One tablet each of BR1019-1 and BR1019-2 administered in combination once daily for 7 days.
|
| Experimental: Sequence 2 The Investigational products will be administered according to the treatment groups(A,B,C) assigned to each sequence group in Period 1, Period 2, and Period 3. *sequence 2: A-C-B |
Drug: BR1019-1
Treatment group A : One tablet of BR1019-1 administered alone once daily for 7 days.
Drug: BR1019-2
Treatment group B : One tablet of BR1019-2 administered alone once daily for 7 days.
Drug: BR1019-1 + BR1019-2
Treatment group C : One tablet each of BR1019-1 and BR1019-2 administered in combination once daily for 7 days.
|
| Experimental: Sequence 3 The Investigational products will be administered according to the treatment groups(A,B,C) assigned to each sequence group in Period 1, Period 2, and Period 3. *sequence 3: B-A-C |
Drug: BR1019-1
Treatment group A : One tablet of BR1019-1 administered alone once daily for 7 days.
Drug: BR1019-2
Treatment group B : One tablet of BR1019-2 administered alone once daily for 7 days.
Drug: BR1019-1 + BR1019-2
Treatment group C : One tablet each of BR1019-1 and BR1019-2 administered in combination once daily for 7 days.
|
| Experimental: Sequence 4 The Investigational products will be administered according to the treatment groups(A,B,C) assigned to each sequence group in Period 1, Period 2, and Period 3. *sequence 4: B-C-A |
Drug: BR1019-1
Treatment group A : One tablet of BR1019-1 administered alone once daily for 7 days.
Drug: BR1019-2
Treatment group B : One tablet of BR1019-2 administered alone once daily for 7 days.
Drug: BR1019-1 + BR1019-2
Treatment group C : One tablet each of BR1019-1 and BR1019-2 administered in combination once daily for 7 days.
|
| Experimental: Sequence 5 The Investigational products will be administered according to the treatment groups(A,B,C) assigned to each sequence group in Period 1, Period 2, and Period 3. *sequence 5: C-A-B |
Drug: BR1019-1
Treatment group A : One tablet of BR1019-1 administered alone once daily for 7 days.
Drug: BR1019-2
Treatment group B : One tablet of BR1019-2 administered alone once daily for 7 days.
Drug: BR1019-1 + BR1019-2
Treatment group C : One tablet each of BR1019-1 and BR1019-2 administered in combination once daily for 7 days.
|
| Experimental: Sequence 6 The Investigational products will be administered according to the treatment groups(A,B,C) assigned to each sequence group in Period 1, Period 2, and Period 3. *sequence 6: C-B-A |
Drug: BR1019-1
Treatment group A : One tablet of BR1019-1 administered alone once daily for 7 days.
Drug: BR1019-2
Treatment group B : One tablet of BR1019-2 administered alone once daily for 7 days.
Drug: BR1019-1 + BR1019-2
Treatment group C : One tablet each of BR1019-1 and BR1019-2 administered in combination once daily for 7 days.
|
Outcome Measures
Primary Outcome Measures
- AUC0-24,ss [0-48 hours after administration]
Area under the concentration-time curve from 0 h to 24 h of BR1019-1 and BR1019-2 at steady-state
- Cmax,ss [0-48 hours after administration]
Maximum concentration of drug in plasma of BR1019-1 and BR1019-2 at steady-state
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Healthy adults aged 19 to 55 years at screening
-
Those who voluntarily decide to participate in the study and provide written consent to follow the study directions after listening to and fully understanding the detailed explanation on this study
Exclusion Criteria:
-
Those who have clinically significant diseases associated with the cardiovascular system, respiratory system, liver, kidney, nervous system, endocrine system, blood/tumor, psychiatric disorders, or urinary system, as well as drug abuse, or a history thereof.
-
Those who took any prescription drugs or herbal medicines within 14 days prior to the first day of administration or any over-the-counter (OTC) drugs within 7 days prior to the first day of administration (however, if other conditions are appropriate according to the judgment of the investigator, they may participate in the clinical study.)
-
Those who took drugs inducing and inhibiting drug-metabolizing enzymes, such as barbiturates, within 30 days prior to the study initiation.
-
Those who have been on a diet (especially grapefruit juice or its products) that may affect the absorption, distribution, metabolism, and excretion of the drug within 7 days prior to the first day of administration.
-
Pregnant women, potentially pregnant women, or breast-feeding women Those who do not agree to rule out the possibility of their and their spouses' or sexual partners' pregnancy by using medically acceptable methods of contraception* throughout the entire period from the date of the first administration of the investigational product to the end of the clinical study
-
Medically acceptable methods of contraception: Combined use of intrauterine device, vasectomy, tubal ligation, and barrier methods (male condom, female condom, cervical cap, diaphragm, sponge, etc.) or combined use of two or more barrier methods if spermicide is used
-
Those who are unwilling or unable to comply with the dietary and lifestyle guidelines required for the clinical study
-
Those who have clinically significant abnormalities in the results of other clinical laboratory tests or who have been determined by the investigator to be ineligible to participate in the clinical study due to other reasons (e.g., non-compliance with instructions, uncooperative attitude, etc.)
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Inha University Hospital | Incheon | Korea, Republic of |
Sponsors and Collaborators
- Boryung Pharmaceutical Co., Ltd
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- BR-FDC-CT-101